Excimer Laser Coronary Angioplasty: Clinical Applications and Procedural Outcome, in a Large-Volume Tertiary Centre.

Angioplasty Calcified coronary arteries Coronary artery disease In-stent restenosis Laser Percutaneous coronary intervention Resistant coronary lesions Undilatable coronary lesions

Journal

Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406

Informations de publication

Date de publication:
2021
Historique:
received: 27 03 2020
accepted: 14 11 2020
pubmed: 8 2 2021
medline: 1 9 2021
entrez: 7 2 2021
Statut: ppublish

Résumé

Excimer-laser coronary angioplasty can be used to modify undilatable and uncrossable lesions in native arteries and in-stent restenosis which are increasingly encountered with the ageing population undergoing coronary intervention. We present our laser experience over a 10-year period in a large cardiac tertiary centre. Retrospective analysis of prospectively collected data on all procedures where laser was used from August 2008 to December 2019. Clinical presentation, demographics, and procedural details were all recorded. Successful procedures were defined as <30% stenosis at the end. Periprocedural and in-hospital complications were recorded and verified. Results are presented as numbers and percentages. A total of 331 patients were identified with 473 lesions treated with laser and an overall total of 637 lesions. Of the 473 lesions treated, 46 (9.9%) were in-stent restenosis, 146 (30.9%) were chronic total occlusions, and the rest were uncrossable or undilatable lesions. The vast majority of procedures (97.0%) were performed with the 0.9-mm laser catheter. The overall success rate was 81.6% (58-87%) from low- to high-volume user. Complications included dissection 3 (0.6%), no-reflow 3 (0.6%), coronary perforation 13 (2.7%), and tamponade in 1 (0.2%). Only 3 (0.6%) of the perforations were seen after the laser catheter passage, the rest were seen later following balloon preparation or stent insertion. Laser is a valuable tool for treating complex and resistant coronary lesions. Its efficacy and safety are well established and when applied appropriately, it helps to achieve optimal outcomes for our patients.

Identifiants

pubmed: 33550306
pii: 000513142
doi: 10.1159/000513142
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

137-143

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Conor McQuillan (C)

Cardiac Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

Mohamed Farag (M)

Cardiac Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

Mohaned Egred (M)

Cardiac Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom, m.egred@nhs.net.
Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom, m.egred@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH